Options to Overcome Clopidogrel Response Variability
نویسندگان
چکیده
منابع مشابه
Options to overcome clopidogrel response variability.
Oral antiplatelet agents targeting the platelet P2Y12 receptor are an integral component of treating patients with acute coronary syndrome and those undergoing percutaneous coronary intervention. Clopidogrel has been the most commonly used agent in this respect worldwide. However, there are certain shortcomings of clopdiogrel, the most important of which is the wide response variability of plat...
متن کاملGenetic variability in response to clopidogrel therapy: clinical implications.
In the past few years, it has been realized that cardiovascular events under dual antiplatelet therapy (DAPT) might be associated with a poor response to clopidogrel. Based on different platelet function assays, 20–25% of clopidogrel-treated patients undergoing percutaneous coronary intervention (PCI) and coronary stenting have been defined as poor responders and were prone to an increased risk...
متن کاملVariability in response to clopidogrel: where is the threshold for 'low response'?
We read with great interest the well-written review about levosimendan by De Luca et al. Levosimendan is certainly an interesting drug that appears to deliver favourable effects in patients with acute heart failure. Numerous studies have demonstrated the positive inotropic action of levosimendan. In 1998, Lilleberg et al. published in this journal an interesting article, which is quoted very of...
متن کاملEvidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance': a rebuttal.
BACKGROUND Clopidogrel is a widely used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor. There is increasing interest in 'clopidogrel resistance'. OBJECTIVES To determine whether 'clopidogrel resistance' is accounted for by a pre-existent variability in platelet response to ADP. METHODS Platelet response to 20 microm ADP was analyzed by four inde...
متن کاملGenetic variability in response to clopidogrel therapy and its clinical implications.
This article concentrates on individual genetic differences responsible for variations of action of clopidogrel, which have been found to be partially responsible for increased cardiovascular events in patients with coronary artery disease under dual antiplatelet therapy. According to these results, genotyping for the relevant gene polymorphisms, especially for the CYP2C19 loss-of-function alle...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation Journal
سال: 2012
ISSN: 1346-9843,1347-4820
DOI: 10.1253/circj.cj-11-1494